Challenges in drug discovery and description targeting Leishmania spp.: enzymes, structural proteins, and transporters
Leishmaniasis is a complex tropical disease caused by the protozoan parasite Leishmania spp. Classical chemotherapy includes pentavalent antimonial; however, pentamidine, amphotericin B, and miltefosine have been used. Chemo-resistance remains a risk for successful treatment; thus, target identifica...
Main Authors: | Alexis Mendoza-León, María Luisa Serrano G., Alicia Ponte-Sucre |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-11-01
|
Series: | Frontiers in Tropical Diseases |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fitd.2023.1241044/full |
Similar Items
-
Sensitivity of Leishmania spp. to Glibenclamide and 4-Aminopiridine: A Tool for the Study of Drug Resistance Development
by: Alicia Ponte-Sucre, et al.
Published: (1997-09-01) -
Microtubule‐targeting agents for cancer treatment: Seven binding sites and three strategies
by: Xingyu Wang, et al.
Published: (2023-09-01) -
Parasite and bacterial co-infections with Leishmania spp. in dogs
by: Virginia Maria Góes da Silva, et al.
Published: (2024-03-01) -
High Selectivity of 8-Hydroxyquinoline on <i>Leishmania (Leishmania)</i> and <i>Leishmania (Viannia)</i> Species Correlates with a Potent Therapeutic Activity In Vivo
by: Sarah Kymberly Santos de Lima, et al.
Published: (2023-05-01) -
The microtubule cytoskeleton: An old validated target for novel therapeutic drugs
by: Laurence Lafanechère
Published: (2022-09-01)